ArticleFrontiers in aging neuroscience2026
Epigenetic memory and allostatic integrity: a theoretical integration of the hierarchical-circular model using a longitudinal methylation signature of dementia.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The Hierarchical-Circular Model of Biological Memory (HCM) proposes that dementia results from disrupted circular information flow across five levels: genetic, epigenetic, allostatic, PNEI network, and interoceptive. Allostatic integrity-the adaptive capacity for circular flow-determines whether pathology translates into dementia. Objective: To evaluate whether a recently published blood DNA methylation signature for incident dementia is consistent with the predictions of the HCM. Methods: We systematically mapped Zhang et al.'s findings (44 CpGs, 44 DMRs, pathway enrichments, methylation risk score) to HCM levels and predictions. We interpreted these findings as providing indirect and conceptual support for the model rather than direct empirical validation. Results: The 44 CpGs/DMRs linked to dementia were enriched in immune and metabolic pathways. Their methylation risk score predicted cognitive decline independently of age, sex, APOEε4, education, and MMSE. These findings are consistent with the HCM's Level 2 (epigenetic memory), Levels 3-4 (allostatic load/PNEI), and Predictions 1 (composite biomarkers outperform single) and 4 (allostatic integrity moderates reserve). Discussion: Epigenetic changes precede dementia, supporting Level 2 as an early event. Immune/metabolic pathways link to allostatic load. Independence from APOEε4/education is consistent with allostatic integrity being distinct from genetic risk and reserve. Conclusion: Zhang et al.'s study provides large-scale evidence that blood DNA methylation may serve as a peripheral biomarker of lost allostatic integrity, consistent with the HCM and supporting a shift from linear to circular, multilevel frameworks for dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.